Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Acts as a transcriptional coactivator for NOTCH proteins. Additionally we are shipping and many more products for this protein.
Showing 10 out of 87 products:
Human Polyclonal MAML2 Primary Antibody for IHC, IP - ABIN151565
Oyama, Harigaya, Sasaki, Okamura, Kokubo, Saga, Hozumi, Suganami, Tamura, Nagase, Koga, Nishimura, Sakamoto, Sato, Yoshida, Kitagawa: Mastermind-like 1 (MamL1) and mastermind-like 3 (MamL3) are essential for Notch signaling in vivo. in Development (Cambridge, England) 2011
findings suggest further characterization of MECs is needed before considering the CRTC1 (show CRTC1 Antibodies)/3-MAML2 gene fusion as a prognostic biomarker
It is, to our knowledge, the first case of B acute lymphoblastic leukemia with this fusion gene. At the molecular level, two rearrangements were detected using RNA sequencing juxtaposing exon 7 to exon 2 and exon 9 to intron 1-2 of the KMT2A (show MLL Antibodies) and MAML2 genes respectively, and one rearrangement using Sanger sequencing juxtaposing exon 8 and exon 2.
we demonstrated that MDM2 (show MDM2 Antibodies) is frequently overexpressed in clear cell carcinomas, and that MDM2 (show MDM2 Antibodies) overexpression is associated with poor prognosis.
Warthin-like mucoepidermoid carcinoma (MEC (show CCL28 Antibodies)), and now a ciliated form of MEC (show CCL28 Antibodies), are newly described variants of a common salivary gland carcinoma. MAML2 rearrangements were identified in all cases. These unusual variants appear to consistently harbor MAML2 fusions-a finding that establishes a clear link to conventional MEC (show CCL28 Antibodies).
MECT1 (show CRTC1 Antibodies)-MAML2 fusion transcript is a driver genetic event in the pathogenesis of primary bronchopulmonary mucoepidermoid carcinoma
A subgroup of MAML2 fusion-negative mucoepidermoid carcinomas are actually clear cell carcinoma of the salivary gland with EWSR1 (show EWSR1 Antibodies) translocation.
This condensed chromatin structure is associated with binding of DNMT3B (show DNMT3B Antibodies) and decreased occupancy of OCT1 (show POU2F1 Antibodies) transcription factor at MAML2 enhancer, suggesting a role of DNMT3B (show DNMT3B Antibodies) in increasing methylation of MAML2 after stilbenoid treatment.
revealing neither correlation between the cellular composition and CRTC1 (show CRTC1 Antibodies)-MAML2 fusions nor presence of CRTC3 (show CRTC3 Antibodies)-MAML2 fusions in cutaneous hidradenoma
MAML2 rearrangement is common and specific for MEC (show CCL28 Antibodies), which makes it a useful diagnostic tool. MAML2 rearrangement also predicts a favorable prognosis.
Detection of the CRTC1 (show CRTC1 Antibodies)/MAML2 fusion transcript provides useful information for MEC (show CCL28 Antibodies) diagnosis but is not associated with differences in survival outcomes.
Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3 (By similarity).
mastermind like 2
, mastermind-like 2
, mastermind-like protein 2